Toll Free: 1-888-928-9744

Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) - Pipeline Review, H2 2016

Published: Aug, 2016 | Pages: 70 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)

Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) - Pipeline Review, H2 2016

Summary

Global Markets Direct's, 'Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) - Pipeline Review, H2 2016', provides in depth analysis on Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) targeted pipeline therapeutics. 

The report provides comprehensive information on the Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) targeted therapeutics development and features dormant and discontinued projects.

Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape for Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11)
- The report reviews Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages 
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities 
- The report reviews key players involved in Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) targeted therapeutics and enlists all their major and minor projects 
- The report assesses Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 
- The report summarizes all the dormant and discontinued pipeline projects 
- The report reviews latest news and deals related to Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) targeted therapeutics

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage 
- Identify and understand the targeted therapy areas and indications for Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies 
- Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
 Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 6 Introduction 7 Global Markets Direct Report Coverage 7 Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) Overview 8 Therapeutics Development 9 Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) - Products under Development by Stage of Development 9 Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) - Products under Development by Therapy Area 10 Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) - Products under Development by Indication 11 Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) - Pipeline Products Glance 12 Late Stage Products 12 Early Stage Products 13 Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) - Products under Development by Companies 14 Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) - Products under Development by Universities/Institutes 16 Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) - Therapeutics Assessment 18 Assessment by Monotherapy/Combination Products 18 Assessment by Mechanism of Action 19 Assessment by Route of Administration 20 Assessment by Molecule Type 22 Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) - Companies Involved in Therapeutics Development 24 Ablynx NV 24 AlphaMab Co., Ltd 25 Amgen Inc. 26 Astellas Pharma Inc. 27 Clonz Biotech Private Limited 28 Intas Pharmaceuticals Ltd. 29 Oncobiologics, Inc. 30 R-Pharm 31 Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) - Drug Profiles 32 ALX-0141 - Drug Profile 32 Product Description 32 Mechanism Of Action 32 R&D Progress 32 AMG-161 - Drug Profile 34 Product Description 34 Mechanism Of Action 34 R&D Progress 34 CDRI-99/373 - Drug Profile 35 Product Description 35 Mechanism Of Action 35 R&D Progress 35 denosumab - Drug Profile 36 Product Description 36 Mechanism Of Action 36 R&D Progress 36 denosumab biosimilar - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 denosumab biosimilar - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 denosumab biosimilar - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 denosumab biosimilar - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 KN-012 - Drug Profile 49 Product Description 49 Mechanism Of Action 49 R&D Progress 49 Monoclonal Antibody to Inhibit RANKL for Bone Disorders - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 Proteins to Inhibit RANKL for Oncology and Osteoporosis - Drug Profile 51 Product Description 51 Mechanism Of Action 51 R&D Progress 51 RPH-203 - Drug Profile 52 Product Description 52 Mechanism Of Action 52 R&D Progress 52 Small Molecules to Inhibit RANKL for Osteoclastogenesis - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) - Dormant Projects 54 Tumor Necrosis Factor Ligand Superfamily Member 11 (Receptor Activator Of Nuclear Factor Kappa B Ligand or Osteoclast Differentiation Factor or TNF Related Activation Induced Cytokine or Osteoprotegerin Ligand or CD254 or TNFSF11) - Featured News & Press Releases 55 Mar 30, 2016: Daiichi Sankyo Announces Phase 3 Clinical Trial Results for AMG 162 (denosumab) Rheumatoid Arthritis Treatment 55 Oct 12, 2015: New Data Show Consistent Safety Profile For Up To 10 Years With Prolia In Postmenopausal Women With Osteoporosis 55 Oct 11, 2015: New Data Show Greater Bone Mineral Density Gains With Prolia Compared With Zoledronic Acid 56 Oct 06, 2015: Amgen To Present Data From Multiple Studies For Prolia On Osteoporosis Disease And Treatment At American Society For Bone And Mineral Research Annual Meeting 57 Jul 06, 2015: R-Pharm Group of Companies Develops Original drug for Treatment of Metastatic Bone Disease 59 Jun 01, 2015: Amgen Presents Phase 3 Data At ASCO Showing Prolia (Denosumab) Significantly Reduced Bone Fractures In Breast Cancer Patients Receiving Aromatase Inhibitors 60 May 13, 2015: Amgen Presents Data At ASCO 2015 On Prolia 61 Sep 15, 2014: Amgen Announces Results From Several New Exploratory Analyses Evaluating Long-Term Impact Of Treatment With Prolia (Denosumab) In Postmenopausal Women With Osteoporosis 61 Sep 10, 2014: Amgen Announces 18 Abstracts To Be Presented At The American Society for Bone and Mineral Research 2014 Annual Meeting 63 Oct 04, 2013: Amgen Presents Data From Several Prolia Studies At ASBMR 64 Jun 11, 2013: Daiichi Sankyo Launches Pralia Subcutaneous Injection 60mg Syringe For Treatment Of Osteoporosis 65 Mar 25, 2013: Daiichi Sankyo Receives Japanese Approval For Manufacture And Marketing Of Pralia For Treatment Of Osteoporosis 66 Nov 21, 2012: Amgen Canada Provides New Safety Information For Prolia 66 Oct 15, 2012: Daiichi Sankyo Announces Positive Phase III Study Results For Denosumab On Fracture Risk In Japanese Patients With Osteoporosis At ASBMR 67 Oct 14, 2012: Amgen Presents Several Sub-Analysis From Pivotal Phase III Prolia Fracture Trial At ASBMR 2012 67 Appendix 69 Methodology 69 Coverage 69 Secondary Research 69 Primary Research 69 Expert Panel Validation 69 Contact Us 69 Disclaimer 70
List of Tables
Number of Products under Development for, H2 2016 9 Number of Products under Development by Therapy Area, H2 2016 10 Number of Products under Development by Indication, H2 2016 11 Comparative Analysis by Late Stage Development, H2 2016 12 Comparative Analysis by Early Stage Products, H2 2016 13 Number of Products under Development by Companies, H2 2016 14 Products under Development by Companies, H2 2016 15 Number of Products under Investigation by Universities/Institutes, H2 2016 16 Products under Investigation by Universities/Institutes, H2 2016 17 Assessment by Monotherapy/Combination Products, H2 2016 18 Number of Products by Stage and Mechanism of Action, H2 2016 19 Number of Products by Stage and Route of Administration, H2 2016 21 Number of Products by Stage and Molecule Type, H2 2016 23 Pipeline by Ablynx NV, H2 2016 24 Pipeline by AlphaMab Co., Ltd, H2 2016 25 Pipeline by Amgen Inc., H2 2016 26 Pipeline by Astellas Pharma Inc., H2 2016 27 Pipeline by Clonz Biotech Private Limited, H2 2016 28 Pipeline by Intas Pharmaceuticals Ltd., H2 2016 29 Pipeline by Oncobiologics, Inc., H2 2016 30 Pipeline by R-Pharm, H2 2016 31 Dormant Projects, H2 2016 54



To request a free sample copy of this report, please complete the form below.

We never share your personal data. Privacy policy
Interested in this report? Get your FREE sample now! Get a Free Sample
Choose License Type
Single User - US $3500
Multi User - US $7000
Hexareeasearch Know

Did you know?

Research Assistance

Phone: 1-415-349-0054

Toll Free: 1-888-928-9744

Email: [email protected]

Why to buy from us

Custom research service

Speak to the report author to design an exclusive study to serve your research needs.

Information security

Your personal and confidential information is safe and secure.

verify